H.C. Wainwright analyst Ed Arce maintained a Buy rating on Conatus Pharmaceuticals (CNAT) today and set a price target of $8. The company’s shares opened today at $2.06, close to its 52-week low of $1.15.
Arce observed:
“916-3963, Probability of success (POS) Prob-adj Value Full value S/O as of POLT, U.S. 55% $0.25 $0.46 Shares outstanding 33,165 Emricasan for cirrhosis, U.S.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.9% and a 40.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on Conatus Pharmaceuticals is a Moderate Buy with an average price target of $9, implying a 336.9% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.39 and a one-year low of $1.15. Currently, Conatus Pharmaceuticals has an average volume of 645.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases.
